

Generalized Anxiety Disorder and Panic Disorder

Fatemah Samir Smaïsem*

Department of Psychiatry, College of Medicine, Al-Maarefa University, Ad Diriyah, Saudi Arabia

Commentary

Generalized Anxiety Disorder (GAD) and Panic Disorder (PD) are among the most common mental disorders in the United States, and they can negatively impact a patient's quality of life and disrupt important activities of daily living. Evidence suggests that the rates of missed diagnoses and misdiagnosis of GAD and PD are high, with symptoms often ascribed to physical causes. Diagnosing GAD and PD requires a broad differential and caution to identify confounding variables and comorbid conditions. Screening and monitoring tools can be used to help make the diagnosis and monitor response to therapy. The GAD-7 and the Severity Measure for Panic Disorder are free diagnostic tools. Successful outcomes may require a combination of treatment modalities tailored to the individual patient. Treatment often includes medications such as selective serotonin reuptake inhibitors and/or psychotherapy, both of which are highly effective. Among psychotherapeutic treatments, cognitive behavior therapy has been studied widely and has an extensive evidence base. Benzodiazepines are effective in reducing anxiety symptoms, but their use is limited by risk of abuse and adverse effect profiles. 2 Physical activities can reduce symptoms of GAD and PD. A number of complementary and alternative treatments are often used; however, evidence is limited for most. Several common botanicals and supplements can potentiate serotonin syndrome when used in combination with antidepressants. Medication should be continued for 12 months before tapering to prevent relapse. Generalized Anxiety Disorder (GAD) and panic disorder (PD) are among the most common mental disorders in the United States and are often encountered by primary care physicians. The hallmark of GAD is excessive, out-of-control worry, and PD is characterized by recurrent and unexpected panic attacks. Both conditions can negatively impact a patient's quality of life and disrupt important activities of daily living. The rates of missed diagnoses and misdiagnosis of GAD and PD are high, with symptoms often ascribed to physical causes. Epidemiology, Etiology, and Pathophysiology of GAD and PD The 12-month prevalence for GAD and PD among U.S. adults 18 to 64 years of age is 2.9% and 3.1%, respectively. In this population, the lifetime prevalence is 7.7% in women and 4.6% in men for GAD, and is 7.0% in women and 3.3% in men for PD.

The etiology of GAD is not well understood. There are several theoretical models, each with varying degrees of empirical support. An underlying theme to several models is the dysregulation of worry. Emerging evidence suggests that patients with GAD may experience persistent activation of areas of the brain associated with mental activity and introspective thinking following 3 worry inducing stimuli.

Twin studies suggest that environmental and genetic factors are

likely involved. The etiology of PD is also not well understood. The neuroanatomical hypothesis suggests that a genetic environment interaction is likely responsible. Patients with PD may exhibit irregularities in specific brain structures, altered neuronal processes, and dysfunctional corticolimbic interaction during emotional processing. Typical Presentation and Diagnostic Criteria Generalized Anxiety Disorder Patients with GAD typically present with excessive anxiety about ordinary, day-to-day situations. The anxiety is intrusive, causes distress or functional impairment, and often encompasses multiple domains (e.g., finances, work, and health). The anxiety is often associated with physical symptoms, such as sleep disturbance, restlessness, muscle tension, gastrointestinal symptoms, and chronic headaches.

5 Diagnostic and Statistical Manual of Mental Disorders, Some factors associated with GAD include female sex, unmarried status, lower education level, poor health, and presence of life stressors. The age of onset is variable, with a median age of 30 years. A number of scales are available to establish diagnosis and assess severity. The GAD7 has been validated as a diagnostic tool and a severity assessment scale, with a score of 10 or more having good diagnostic sensitivity and specificity. 4 Greater GAD-7 scores correlate with more functional impairment. The scale was developed and validated based on DSM-IV criteria, but it remains clinically useful after publication of the DSM-5 because the differences in GAD diagnostic criteria are minimal. The PROMIS Emotional Distress–Anxiety–Short Form for adults and the Severity Measure for Generalized Anxiety Disorder–Adult, available from the American Psychiatric Association at <http://www.psychiatry.org/practice/dsm/dsm5/onlineassessment-measures>, are intended to aid clinical evaluation of GAD and monitor treatment effectiveness. Panic Disorder (PD) is characterized by episodic, unexpected panic attacks that occur without a clear trigger. Panic attacks are defined by the rapid onset of intense fear (typically peaking within about 10 minutes) with at least four of the physical and psychological symptoms in the DSM-5 diagnostic criteria. Another requirement for the diagnosis of PD is that the patient worries about further attacks or modifies his or her behavior in maladaptive ways to avoid them. The most common physical symptom accompanying panic attacks is palpitations. Although unexpected panic attacks are required for the diagnosis, many patients with PD also have expected panic attacks, occurring in response to a known trigger. Some studies evaluating anxiety treatments assess nonspecific anxiety-related symptoms rather than the set of symptoms that characterize GAD or PD. When possible, the treatments described in this section will differentiate. 5 GAD-7 Screening Tool Over the last 2 weeks, how often have you been bothered by the following problems? Not at all several days More than half the days nearly every day (Use "1" to indicate your answer). Feeling nervous, anxious, or on edge 0 1 2 3 2. Not

*Corresponding Author: Fatemah Samir Smaïsem, Department of Psychiatry, College of Medicine, Al-Maarefa University, Ad Diriyah, Saudi Arabia, Tel: +966920011909; E-mail: fatemasamirdr@gmail.com

Copyright: © 2021 Smaïsem FS. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received:22 March,2021; Accepted:06 April2021;Published:April13,2021

being able to stop or control worrying 0 1 2 3 3. Worrying too much about different things 0 1 2 3 4. Trouble relaxing 0 1 2 3 5. Being so restless that it is hard to sit still 0 1 2 3 6. Becoming easily annoyed or irritable 0 1 2 3 7. Feeling afraid as if something awful might happen 0 1 2 3 Total score=+ + + NOTE: Total score for the 7 items ranges from 0 to 21. Scores of 5, 10, and 15 represent cutoffs for mild, moderate, and severe anxiety, respectively. Although designed primarily as a screening and severity measure for GAD, the GAD-7 also has moderately good operating characteristics for panic disorder, social anxiety disorder, and posttraumatic stress disorder. When

screening for anxiety disorders, a recommended cutoff for further evaluation is a score of 10 or greater. GAD=generalized anxiety disorder. Otherwise, treatments refer to anxiety-related symptoms in general. Medication or psychotherapy is a reasonable initial treatment option for GAD and PD. Some studies suggest that combining medication and psychotherapy may be more effective for patients with moderate to severe symptoms. The National Institute for Health and Care Excellence (NICE) guidelines on GAD and PD in adults are a useful review of available evidence; however, information about self-help and group therapies may have less utility in the United States because of their relative lack of availability.

How to cite this article: Smaiem, Fatemah Samir. "Generalized Anxiety Disorder and Panic Disorder." *Clin Schizophr Relat Psychoses* 14 (2020): 4. DOI: 10.3371/CSRP.SF.092520.